Literature DB >> 16710853

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.

Sara A Corya1, Doug Williamson, Todd M Sanger, Susan D Briggs, Michael Case, Gary Tollefson.   

Abstract

Based on preliminary evidence of its usefulness in treatment-resistant depression (TRD), an olanzapine/fluoxetine combination (OFC) was examined in comparison with olanzapine, fluoxetine, and venlafaxine in a TRD population. In this 12-week double-blind study, 483 subjects with unipolar, nonpsychotic TRD, with historic failure on a selective serotonin reuptake inhibitor (SSRI) and prospective failure on open-label venlafaxine, were randomized to an OFC or to an olanzapine, fluoxetine, or venlafaxine monotherapy group. Venlafaxine was continued randomly in the double-blind acute phase to explore the benefits of continuation versus switching therapy. The Montgomery-Asberg Depression Rating Scale (MADRS) total change score at end point was the primary outcome measure. The OFC group had significantly greater improvement in depressive symptoms by week 1 of treatment (MADRS mean change =-7.2, baseline =29.6), in comparison to olanzapine (-4.8, P=.03), fluoxetine (-4.7, P=.03), or venlafaxine (-3.7, P=.002) groups and maintained its statistical separation from all three monotherapy groups through week 6. At end point, the OFC group was significantly different only from the olanzapine group (-14.1 vs. -7.7, P<.001). Analysis of a subgroup of subjects who had an SSRI failure in their current depressive episode (n=334) revealed statistical separation from both olanzapine and fluoxetine (but not venlafaxine) at end point: OFC (-14.6) versus olanzapine (-9.4, P<.001) versus fluoxetine (-10.7, P=.006) versus venlafaxine (-14.7, P=.98). The OFC had a safety profile comparable to its component monotherapies (i.e., olanzapine and fluoxetine), showed a rapid onset of antidepressant effect, and was effective in this TRD sample. At the study end point, OFC, fluoxetine, venlafaxine, and low-dose OFC all appeared to be similarly effective.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16710853     DOI: 10.1002/da.20130

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  40 in total

Review 1.  How should primary care doctors select which antidepressants to administer?

Authors:  Gerald Gartlehner; Kylie Thaler; Seth Hill; Richard A Hansen
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

2.  Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex.

Authors:  N A Muma; R K Singh; M S Vercillo; D N D'Souza; B Zemaitaitis; F Garcia; K J Damjanoska; Y Zhang; G Battaglia; L D Van de Kar
Journal:  Neuropharmacology       Date:  2007-07-01       Impact factor: 5.250

3.  National trends in second-generation antipsychotic augmentation for nonpsychotic depression.

Authors:  Tobias Gerhard; Ayse Akincigil; Christoph U Correll; Neil J Foglio; Stephen Crystal; Mark Olfson
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

Review 4.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 5.  Use of atypical antipsychotics for treatment-resistant major depressive disorder.

Authors:  George I Papakostas; Richard C Shelton
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

Review 6.  Novel targets for antidepressant therapies.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

7.  Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.

Authors:  William V Bobo; Richard C Shelton
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

8.  Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression.

Authors:  Laura Gedge; Lauren Lazowski; David Murray; Ruzica Jokic; Roumen Milev
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

9.  A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression.

Authors:  Gabor I Keitner; Steven J Garlow; Christine E Ryan; Philip T Ninan; David A Solomon; Charles B Nemeroff; Martin B Keller
Journal:  J Psychiatr Res       Date:  2008-06-30       Impact factor: 4.791

10.  Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.

Authors:  Lijun Tan; Jiangtao Liu; Xiuli Liu; Jie Chen; Zhijun Yan; Huifen Yang; Daxin Zhang
Journal:  J Exp Clin Cancer Res       Date:  2009-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.